Find Reports
Select Report Type
Reimbursement Review
Displaying 201 - 225 of 1422
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| nivolumab | Opdivo | nivolumab | Urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0272-000 | |||
| selpercatinib | Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0264-000 | |||
| semaglutide | Wegovy | semaglutide | Weight management | Do not reimburse | Complete | SR0725-000 | |||
| ruxolitinib | Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | SR0688-000 | |||
| pembrolizumab and lenvatinib | Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0288-000 | |||
| Renal Cell Carcinoma (RCC) | Renal Cell Carcinoma (RCC) | Complete | PH0013-000 | ||||||
| atezolizumab | Tecentriq | atezolizumab | Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0277-000 | |||
| atezolizumab | Tecentriq | atezolizumab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0269-000 | |||
| pembrolizumab | Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0279-000 | |||
| tepotinib | Tepmetko | tepotinib | Locally advanced or metastatic non-small cell lung cancer | Do not reimburse | Complete | PC0255-000 | |||
| dostarlimab | Jemperli | dostarlimab | Endometrial cancer | Do not reimburse | Complete | PC0263-000 | |||
| abrocitinib | Cibinqo | abrocitinib | Atopic dermatitis, moderate to severe | Reimburse with clinical criteria and/or conditions | Complete | SR0686-000 | |||
| faricimab | Vabysmo | faricimab | Macular degeneration, age-related | Reimburse with clinical criteria and/or conditions | Complete | SR0719-000 | |||
| mogamulizumab | Poteligeo | mogamulizumab | mycosis fungoides (MF), Sézary syndrome (SS) | Reimburse with clinical criteria and/or conditions | Complete | PC0244-000 | |||
| nusinersen | Spinraza | nusinersen | Spinal Muscular Atrophy | Do not reimburse | Complete | SR0713-000 | |||
| asciminib | Scemblix | asciminib | Philadelphia chromosome-positive chronic myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | PC0275-000 | |||
| NSCLC without actionable oncog... | Unmutated Non-small cell lung cancer | Complete | PH0012-000 | ||||||
| selinexor | Xpovio | selinexor | Multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | PC0276-000 | |||
| zanubrutinib | Brukinsa | zanubrutinib | Mantle cell lymphoma (MCL) | Do not reimburse | Complete | PC0267-000 | |||
| sodium phenylbutyrate and urso... | Albrioza | sodium phenylbutyrate and ursodoxicoltaurine | Amyotrophic lateral sclerosis (ALS) | Reimburse with clinical criteria and/or conditions | Complete | SR0711-000 | |||
| ruxolitinib | Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | SR0706-000 | |||
| avalglucosidase alfa | Nexviazyme | avalglucosidase alfa | Pompe disease | Reimburse with clinical criteria and/or conditions | Complete | SR0703-000 | |||
| lisocabtagene maraleucel | Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | PG0258-000 | |||
| selpercatinib | Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0274-000 | |||
| lenvatinib and pembrolizumab | Lenvima and Keytruda | lenvatinib and pembrolizumab | advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0268-000 |
Health Technology Review
Displaying 201 - 225 of 600
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 201 - 225 of 2132
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| pembrolizumab | Reimbursement Review | Complete | PC0273-000 | ||||
| ripretinib | Reimbursement Review | Complete | PC0265-000 | ||||
| tebentafusp | Reimbursement Review | Complete | PC0290-000 | ||||
| daratumumab | Reimbursement Review | Complete | PC0257-000 | ||||
| nivolumab | Reimbursement Review | Complete | PC0259-000 | ||||
| tepotinib | Reimbursement Review | Complete | PC0255-000 | ||||
| sacituzumab govitecan | Reimbursement Review | Complete | PC0254-000 | ||||
| nivolumab | Reimbursement Review | Complete | PC0253-000 | ||||
| enfortumab vedotin | Reimbursement Review | Complete | PC0251-000 | ||||
| lorlatinib | Reimbursement Review | Complete | PC0249-000 | ||||
| osimertinib | Reimbursement Review | Complete | PC0246-000 | ||||
| venetoclax | Reimbursement Review | Complete | PC0238-000 | ||||
| pembrolizumab | Reimbursement Review | Complete | PC0236-000 | ||||
| nivolumab-ipilimumab | Reimbursement Review | Complete | PC0229-000 | ||||
| pembrolizumab | Reimbursement Review | Complete | PC0235-000 | ||||
| Acalabrutinib | Reimbursement Review | Complete | PC0211-000 | ||||
| Nivolumab-Ipilimumab | Reimbursement Review | Complete | PC0218-000 | ||||
| pembrolizumab | Reimbursement Review | Complete | PC0286-000 | ||||
| brexucabtagene autoleucel | Reimbursement Review | Complete | PG0304-000 | ||||
| Acute Myeloid Leukemia | Reimbursement Review | Provisional Funding Algorithm | In Progress | PH0082-000 | |||
| Non Small Cell Lung Cancer | Reimbursement Review | Provisional Funding Algorithm | Open for Input | PH0085-000 | |||
| foslevodopa foscarbidopa | Reimbursement Review | Complete | SR0768-000 | ||||
| Prostate cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0057-000 | |||
| risankizumab | Reimbursement Review | Complete | SR0767-000 | ||||
| Anaplastic Lymphoma Kinase (ALK) -Positive Non-small Cell Lung Cancer (NSCLC) | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0058-000 |